Pre-eclampsia Pregnancy and Childbirth Pre-eclampsia
Conditions
Interventions
Magnesium sulphate/placebo.
Follow-up: until discharge following delivery. Four year follow-up of the children is planned.
Sponsors
Medical Research Council (MRC) (UK)
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1. Not delivered, or delivered within the last 24 hours 2. Blood pressure today is =90 mmHg diastolic or =140 mmHg systolic, on at least two occasions 3. Proteinuria of at least 1+ 4. There is clinical uncertainty about whether magnesium sulphate would be beneficial (factors likely to influence this uncertainty are the presence of any of the following: hypereflexia, frontal headache, abnormal liver function or coagulation, and epigastric tenderness)
Exclusion criteria
Exclusion criteria: The woman does not wish to be randomised, for whatever reason/the attending clinician believes magnesium sulphate should either be given or withheld/hypersensitivity to magnesium/renal failure (women who have renal impairment may be randomised, but the volume of allocated treatment should be halved for each dose)/hepatic coma if risk of renal failure/myaesthenia gravis.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Eclampsia 2. Death of the baby. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Maternal death 2. Serious maternal morbidity 3. Labour and delivery outcomes 4. Use of maternal health services 5. Serious neonatal morbidity 6. Use of neonatal health services | — |
Countries
Albania, Argentina, Australia, Bangladesh, Brazil, Colombia, Cuba, Egypt, Ghana, India, Malawi, Nigeria, Pakistan, Sierra Leone, Singapore, South Africa, United States of America, Zimbabwe
Outcome results
None listed